Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer

Asia-Pacific Journal of Clinical Oncology

Volumn 7, Issue 4, 2011, Pages 376-384

  Mitchell, Paul L ^a,d   Broad, Adam ^a,d   Rosenthal, Mark A ^b,d   Galettis, Peter ^f   Abraham, Rick ^h   Burns, Ivon ^c   Clarke, Stephen ^g   Milner, Alvin ^e   Diiulio, Juliana ^e   Links, Matthew ^f  

^a AUSTIN HOSPITAL   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d Cancer Trials Australia ^*  (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f ST GEORGE HOSPITAL   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

Gemcitabine; Non small cell lung cancer; Oxaliplatin

Indexed keywords

GEMCITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TOXICITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; ODYNOPHAGIA; OVERALL SURVIVAL; PERFORMANCE; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS;

EID: 83355169644     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2011.01390.x     Document Type: Article

References (24)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Scagliotti GV, Parikh P, von Pawel J etal. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
3. Goldberg RM, Sargent DJ, Morton RF etal. A randomized controlled trial of fluorouracil plus leucovorin, CPT11, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
4. André T, Boni C, Mounedji-Boudiaf L etal. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. New Eng J Med 2004; 350: 2343-51.
5. Extra JM, Espie M, Calvo F etal. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299-303.
6. Pasetto LM, D'Andrea MR, Rossi E etal. Oxaliplatin-related neurotoxicity: how and why? Crit Rev Haem/Oncol 2006; 59: 159-68.
7. Faivre S, Raymond E, Woynarowski JM etal. Supraadditive effect of 2′, 2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999; 44: 117-23.
8. Gan HK, Mitchell PL, Galettis P etal. A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors. Cancer Chemother Pharmacol 2006; 58: 157-64.
9. Shepherd F, Abratt R, Crino L etal. The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer. Lung Cancer 2000; 30: 117-25.
10. Abratt R, Sandler A, Crino L etal. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. Semin. Oncology 1998; 25: 35-43.
11. Therasse P, Arbuck SG, Eisenhauer E etal. Guidelines for response evaluation criteria in solid tumours (RECIST): EORTC, NCI (USA) and NCIC. J Nat Can Inst 2000; 92: 205-16.
12. Rothenburg ML, Oza AM, Bigelow RH etal. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Onc 2004; 126: 1985-93.
13. Kakolyris S, Ziras N, Vamvakas L etal. Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study. Lung Cancer 2006; 54: 347-52.
14. André T, Tournigand C, Rosmorduc O etal. Gemcitabine compared with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Annals Oncol 2004; 15: 1339-43.
15. Ziras N, Potimianou A, Varthalitis I etal. Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. Oncology 2006; 70: 106-14.
16. Raspagliesi F, Zanaboni F, Vecchione F etal. Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane. Oncology 2004; 67: 376-81.
17. Mir O, Alexandre J, Ropert S etal. Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe or cardiac comorbidities. Anti-cancer Drugs 2005; 16: 1017-21.
18. Sampol A, Rodriguez J, Galmés B etal. Gemcitabine and oxaliplatinum: an effective regimen in a patient with progressive refractory mantle cell lymphoma. Leuk Lymphoma 2004; 45: 1289-91.
19. Louvet C, Labianca R, Hammel P etal. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III Trial. J Clin Oncol 2005; 23: 3509-16.
20. Cappuzzo F, Novello S, De Marinis F etal. Phase II study of gemcitabine plus oxaliplatin as first line chemotherapy for advanced non-small cell lung cancer. Br J Cancer 2005; 93: 29-34.
21. Bidoli P, Zilembo N, Cortinovis D etal. Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology Trial. Ann Oncol 2007; 18: 461-7.
22. Franciosi V, Barbieri R, Aitini E etal. Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients. Lung Cancer 2003; 41: 101-6.
23. Faivre S, Le Chevalier T, Monnerat C etal. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small cell lung cancer and ovarian cancer. Annals of. Oncology 2002; 13: 1479-89.
24. Jiang X, Galettis P, Links M, Mitchell PL, McLachlan AJ. Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. Br J Pharmacol 2008; 65: 326-33.